Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Serono secures license for Rigel’s anticancer candidates
Under the terms of the agreement, Rigel will receive initial payments totaling $25 million, comprised of a license fee of $10 million and purchase of $15 million of
Under the terms of the agreement, Rigel will receive initial payments totaling $25 million, comprised of a license fee of $10 million and purchase of $15 million of
ParAllele stockholders will receive approximately $120.8 million in the form of approximately 2.29 million shares of Affymetrix common stock and $11.7 million in cash in exchange for all
Preclinical research has indicated that Imprime PGG significantly enhanced the effectiveness of monoclonal antibody therapy to both kill tumors and increase long-term survival rates. Imprime PGG recruits and
On September 22, 2004, Ortho-McNeil filed a complaint in the US District Court alleging that Caraco’s filing of an ANDA seeking approval to market the generic version of
Under the terms of the agreement, MN will be responsible for the development and manufacture of all products, whilst Par will provide regulatory affairs support and submit each
In a meeting, the FDA asked ID Biomedical to provide a significant amount of additional information and follow-up from the recently completed adult study prior to further considering
The marketing authorization application filing is based on a pivotal phase II/III trial study that included a total of 155 patients and compared Dyloject to Voltarol and placebo
The completion of the acquisition closes the deal that was first made public when Cardiome announced that it had executed a letter of intent in late August 2005.
Chronic dry eye disease is a common condition characterized by insufficient tear production to lubricate the eye frequently affecting patients with autoimmune disorders. Under the agreement Allergan will
The collaboration is expected to create antibody therapeutics with improved biological properties targeting newly discovered membrane antigens. OncoTherapy Science will employ its technology for identification of the cancer